

Synthesis and Antioxidant Activity of Some 2-Amino-4-aryl-3-cyano-7-(dimethylamino)-4H-chromenes

ALIREZA FOROUMADI*, GHOLAMREZA DEHGHAN,
ALIREZA SAMZADEH-KERMANI†, FATEMEH ARABSORKHI, MAEDEH SORKHI,
ABBAS SHAFIEE and MOHAMMAD ABDOLLAHI
Faculty of Pharmacy and Pharmaceutical Sciences Research Center,
Tehran University of Medical Sciences, Tehran, Iran
Fax: (98)(21)66461178; Tel: (98)(21)66959064; E-mail: aforoumadi @tums.ac.ir

A new series of 2-amino-4-aryl-3-cyano-7-(dimethylamino)-4H-chromenes was synthesized by the condensation of 3-(dimethylamino)phenol, an aromatic aldehyde and malonitrile in ethanol containing piperidine. The assignments of the structure of all the newly synthesized compounds were based on elemental analysis and spectral data (IR, Mass, ¹H NMR). The antioxidant activity of the synthesized compounds was determined by Ferric Reducing Antioxidant Power (FRAP) and DPPH free radical scavenging methods. Several compounds showed significant antioxidant activity.

Key Words: Synthesis, Antioxidants, 4-Aryl-4H-chromenes.

INTRODUCTION


A growing amount of research in biology and medicine has been dedicated to free radicals such as Reactive Oxygen Species (ROS). ROS are required in many living tissues for normal metabolic processes, *e.g.*, phagocytosis, antiinflammation, cell division, and synthesis of collagen¹⁻³. However, there is now considerable evidence that ROS induce oxidative damage in biomolecules especially in proteins, lipids and DNA. This damage causes various degenerative disorders, such as cardiovascular disease, aging, and neurodegenerative disease, like Alzheimer's disease, Parkinson's disease, mutation and cancer^{4,5}. In view of the biological importance of dietary antioxidants in chemoprevention of these diseases, in an effort to develop a novel antioxidant, we have synthesized a series of 4-aryl-4H-chromenes and evaluated their antioxidant activities.

4-Aryl-4H-chromenes have been identified as novel anticancer agents by potent apoptosis inducing activity^{6,7}, but to the best of our knowledge, the 4-aryl-4H-chromenes have not been studied for their antioxidative activity.

†Faculty of Sciences, Tarbiat Modarress University, Tehran, Iran.

EXPERIMENTAL

2-Amino-3-cyano-7-(dimethylamino)-4-(substituted phenyl)-4*H*-chromenes (**3a-m**) were synthesized by the condensation of 3-(dimethylamino)phenol (**1**), a substituted benzaldehyde (**2**) and malonitrile in ethanol in the presence of piperidine (**Scheme-1**). The synthesized compounds were characterized by IR, ¹H NMR, mass spectral data and elemental analysis.



Compounds **3a-m** were screened for their antioxidant activity using ferric reducing antioxidant power (FRAP) and DPPH free radical scavenging methods.

The melting points were taken on a Kofler hot stage apparatus and are uncorrected. IR spectra were recorded on a Shimadzu 470 spectrophotometer (KBr disks). ¹H NMR spectra were recorded on a Bruker FT-80 NMR spectrophotometer using CDCl₃ as solvent and TMS as an internal standard. The purity of the compounds was monitored by thin layer chromatography.

2-Amino-3-cyano-7-(dimethylamino)-4-(substituted phenyl)-4*H*-chromenes (3a-m): (General procedure): Piperidine (10 mmol) was added to a mixture of 3-dimethylaminophenol (**1**, 5 mmol), substituted benzaldehyde (**2**, 5 mmol) and malonitrile (5 mmol) in ethanol (20 mL). The reaction mixture was stirred at 35°C for 12 h. After cooling, the precipitated solid was filtered, washed with cold ethanol and crystallized from the same solvent.

2-Amino-4-(2,3-dimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3a): Yield 56 %; m.p. 157-158°C; m.f. C₂₀H₂₁N₃O₃ IR (KBr, cm⁻¹): 3416, 3313 ν(NH₂), 2176 ν(CN); ¹H NMR (CDCl₃, 80 MHz) δ 7.10-6.90 (m, 1H, aromatic), 6.89-6.60 (m, 3H, aromatic), 6.55-6.33 (m, 2H, aromatic), 4.96(s, 1H, 4*H*-chromene), 4.42 (brs, 2H, NH₂), 3.78(s, 3H), 3.75 (s, 3H), 2.88 (s, 6H, NMe₂); Ms (m/z, %): 351(M⁺, 50), 321(30), 214(100), 198(17), 168(7).

2-Amino-4-(2,4-dimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3b): Yield 40 %; m.p. 145-146°C; m.f. C₂₀H₂₁N₃O₃ IR (KBr, cm⁻¹): 3400, 3318 ν(NH₂), 2187 ν(CN); ¹H NMR

(CDCl₃, 80 MHz) δ : 7.04-6.78 (m, 2H, aromatic), 6.75-6.22 (m, 4H, aromatic), 5.06 (s, 1H, 4*H*-chromene), 4.47 (brs, 2H), 3.81 (s, 3H, OMe), 3.76 (s, 3H, OMe), 2.90 (s, 6H, NMe₂); Ms (m/z, %): 351(M⁺, 100), 334(28), 276(13), 214(90), 198(88), 170(30), 138(16).

2-Amino-4-(2,5-dimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3c): Yield 48%; m.p. 160-162°C; m.f. C₂₀H₂₁N₃O₃ IR (KBr, cm⁻¹): 3400, 3298 ν (NH₂), 2182 ν (CN); ¹H NMR (CDCl₃, 80 MHz) δ : 7.00-6.65 (m, 3H, aromatic), 6.65-6.20 (m, 3H, aromatic), 5.12 (s, 1H, 4*H*-chromene), 4.50 (brs, 2H, NH₂), 3.80 (s, 3H, OMe), 3.69 (s, 3H, OMe), 2.91 (s, 6H, NMe₂); Ms (m/z, %): 351 (M⁺, 35), 320(22), 214(100), 198(17), 167.9(8).

2-Amino-4-(3,4-dimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3d): Yield 42%; m.p. 160-161°C; m.f. C₂₀H₂₁N₃O₃ IR (KBr, cm⁻¹): 3467, 3324 ν (NH₂), 2187 ν (CN); ¹H NMR (CDCl₃, 80 MHz) δ : 6.95-6.61 (m, 3H, aromatic), 6.55-6.45 (m, 1H, aromatic), 6.40-6.29 (m, 2H, aromatic), 4.59 (s, 1H, 4*H*-chromene), 4.53 (brs, 2H, NH₂), 3.84 (s, 3H, OMe), 3.83 (s, 3H, OMe), 2.93 (s, 6H, NMe₂); Ms (m/z, %): 351(M⁺, 93), 334 (14), 276(8), 236(16), 214(100), 198(59), 170(16), 137(20), 97(15), 83(90), 47.1(29).

2-Amino-4-(3,5-dimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3e): Yield 38%; m.p. 170-171°C; m.f. C₂₀H₂₁N₃O₃ IR (KBr, cm⁻¹): 3450, 3325 ν (NH₂), 2185 ν (CN); ¹H NMR (DMSO-d₆, 80 MHz) δ : 6.90-6.46 (m, 3H, aromatic), 6.40-6.35 (m, 1H, aromatic), 6.30-6.20 (m, 2H, aromatic), 4.50 (s, 1H, 4*H*-chromene), 4.33(brs, 2H, NH₂), 3.68 (s, 6H, OMe), 2.88 (s, 6H, NMe₂); Ms (m/z, %): 351(M⁺, 80), 214(100), 198(9).

2-Amino-4-(2,3,4-trimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3f): Yield 48%; m.p. 137-138°C; m.f. C₂₁H₂₃N₃O₄ IR (KBr, cm⁻¹): 3416, 3324 ν (NH₂), 2187 ν (CN); ¹H NMR (CDCl₃, 80 MHz) δ : 7.01-6.21 (m, 5H, aromatic), 4.91 (s, 1H, 4*H*-chromene), 4.51 (brs, 2H, NH₂), 3.95-3.70 (m, 9H, OMe), 2.90 (s, 6H, NMe₂); Ms (m/z, %): 381(M⁺, 60), 350(67), 214(100), 198(30).

2-Amino-4-(3,4,5-trimethoxyphenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3g): Yield 74%; m.p. 177-179°C; m.f. C₂₁H₂₃N₃O₄ IR (KBr, cm⁻¹): 3452, 3329 ν (NH₂), 2197 ν (CN); ¹H NMR (CDCl₃, 80 MHz) δ : 6.90-6.70 (m, 1H, aromatic), 6.65-6.20 (m, 4H, aromatic), 4.57 (brs, 3H, 4*H*-chromene and NH₂), 3.81 (s, 9H, OMe), 2.93 (s, 6H, NMe₂); Ms (m/z, %): 381 (M⁺, 88), 214(100), 198(50).

2-Amino-4-(2-bromophenyl)-7-(dimethylamino)-4*H*-chromene-3-carbonitrile (3h): Yield 49%; m.p. 197-198°C; m.f. C₁₈H₁₆ N₃OBr IR (KBr, cm⁻¹): 3462, 3318 ν (NH₂), 2202 ν (CN); ¹H NMR (CDCl₃, 80 MHz) δ : 7.6-7.5 (m, 1H, aromatic), 7.21-7.01 (m, 3H, aromatic), 7.00-6.71 (m,

1H, aromatic), 6.61-6.21 (m, 2H, aromatic), 5.31 (s, 1H, 4H-chromene), 4.58 (brs, 2H, NH₂), 2.91 (s, 6H, NMe₂); Ms (m/z, %): 371 (M⁺+2, 13), 369 (M⁺, 13), 214(100), 198(15).

2-Amino-4-(3-bromophenyl)-7-(dimethylamino)-4H-chromene-3-carbonitrile (3i): Yield 67 %; m.p. 178-180°C; m.f. C₁₈H₁₆N₃OBr IR (KBr, cm⁻¹): 3457, 3349 ν(NH₂), 2192 ν(CN); ¹H NMR (CDCl₃, 80 MHz) δ: 7.32-7.05 (m, 3H, aromatic), 6.91-6.68 (m, 1H, aromatic), 6.54-6.20 (m, 3H, aromatic), 4.59 (brs, 3H, 4H-chromene and NH₂), 2.92 (s, 6H, NMe₂); Ms (m/z, %): 371(M⁺+2, 95), 369 (M⁺, 98), 368 (56), 354(15), 214(100), 198(15), 170(30), 144(50).

2-Amino-4-(2,3-dichlorophenyl)-7-(dimethylamino)-4H-chromene-3-carbonitrile (3j): Yield 67%; m.p. 207-208°C; m.f. C₁₈H₁₅N₃OCl₂ IR (KBr, cm⁻¹): 3452, 3334 ν(NH₂), 2192 ν(CN); ¹H NMR (CDCl₃, 80 MHz) δ: 7.24-7.15 (m, 1H, aromatic), 7.15-6.98 (m, 2H, aromatic), 6.90-6.65 (m, 1H, aromatic), 6.60-6.45 (m, 1H, aromatic), 6.47-6.25 (m, 1H, aromatic), 4.60 (m, 3H, 4H-chromene and NH₂), 2.94 (s, 6H, NMe₂); Ms (m/z, %): 363 (M⁺+4, 1), 361 (M⁺+2, 6), 359 (M⁺, 8), 214(100), 198(14).

2-Amino-4-(2,6-dichlorophenyl)-7-(dimethylamino)-4H-chromene-3-carbonitrile (3k): Yield 61%; m.p. 255-256°C; m.f. C₁₈H₁₅N₃OCl₂ IR (KBr, cm⁻¹): 3421, 3329 ν(NH₂), 2187 ν(CN); ¹H NMR (DMSO-d₆, 80 MHz) δ: 7.5-7.28 (m, 1H, aromatic), 7.28-6.92 (m, 2H, aromatic), 6.82-6.58 (m, 1H, aromatic), 6.5-6.15 (m, 2H, aromatic), 5.81 (s, 1H, 4H-chromene), 5.28 (brs, 2H, NH₂), 2.91 (s, 6H, NMe₂); Ms (m/z, %): 363 (M⁺+4, 4), 361 (M⁺+2, 24), 359 (M⁺, 37), 279(9), 214(100), 198(57), 170(15), 143(8).

2-Amino-7-(dimethylamino)-4-(2,4-dimethylphenyl)-4H-chromene-3-carbonitrile (3l): Yield 32%; m.p. 100-101°C; m.f. C₂₀H₂₁N₃O IR (KBr, cm⁻¹): 3477, 3313 ν(NH₂), 2192 ν(CN); ¹H NMR (CDCl₃, 80 MHz) δ: 7.05-6.80 (m, 3H, aromatic), 6.8-6.6 (m, 1H, aromatic), 6.55-6.22 (m, 2H, aromatic), 4.92 (s, 1H, 4H-chromene), 4.48 (brs, 2H, NH₂), 2.92 (s, 6H, NMe₂), 2.34 (s, 3H, Me), 2.26 (s, 3H, Me); Ms (m/z, %): 319 (M⁺, 25), 214(100), 198(10).

2-Amino-4-biphenyl-4-yl-7-(dimethylamino)-4H-chromene-3-carbonitrile (3m): Yield 79%; m.p. 216-218°C; m.f. C₂₃H₂₁N₃O IR (KBr, cm⁻¹): 3462, 3308 ν(NH₂), 2187 ν(CN). ¹H NMR (CDCl₃, 80 MHz) δ: 7.7-7.1 (m, 9H, aromatic), 6.84 (d, J=8.8, 1H, aromatic), 6.56-6.28 (m, 2H, aromatic), 4.68 (s, 1H, 4H-chromene), 4.54 (brs, 2H, NH₂), 2.92 (s, 6H, NMe₂); Ms (m/z, %): 367(M⁺, 25), 214(100), 198(9).


RESULTS AND DISCUSSION

In the present study, two commonly used antioxidant evaluation methods, Ferric Reducing Antioxidant Power (FRAP) and the DPPH (1,1-diphe-

nyl-2-picrylhydrazyl) radical scavenging methods, were chosen to determine the antioxidant potential of the compounds.

FRAP assay: The antioxidant capacity of the synthesized compounds was measured using FRAP method⁸. According to the method, reduction of ferric to ferrous ion at low pH cases a coloured ferrous-tripyridyltriazine complex to form. FRAP values are obtained by comparing the absorbance change at 593 nm in test reaction mixtures with those containing ferrous ions in known concentration (Table-1). According to the data presented in Table-1, compound **3k** having 2,6-dichloro substituent showed the most antioxidant power in FRAP assay.

TABLE-1
ANTIOXIDANT ACTIVITY OF 2-AMINO-3-CYANO-7-(DIMETHYLAMINO)-4-(SUBSTITUTED PHENYL)-4H-CHROMENES (**3a-m**)



Comp.	X	FRAP values (μM) ^a	DPPH IC ₅₀ (μM) ^a
3a	2,3-Di CH ₃ O	27.43 \pm 1.41	93.8 \pm 0.84
3b	2,4-Di CH ₃ O	26.23 \pm 1.05	66.73 \pm 0.48
3c	2,5-Di CH ₃ O	24.78 \pm 0.95	424.89 \pm 1.28
3d	3,4-Di CH ₃ O	25.46 \pm 0.93	148.30 \pm 0.69
3e	3,5-Di CH ₃ O	9.38 \pm 0.38	179.61 \pm 2.11
3f	2,3,4-Tri CH ₃ O	25.80 \pm 0.55	81.90 \pm 0.91
3g	3,4,5-Tri CH ₃ O	33.25 \pm 1.07	109.83 \pm 0.54
3h	2-Br	33.82 \pm 0.89	186.94 \pm 1.34
3i	3-Br	33.46 \pm 1.04	> 500
3j	2,3-Di Cl	30.24 \pm 0.47	237.22 \pm 1.58
3k	2,6-Di Cl	35.30 \pm 1.03	681.69 \pm 1.50
3l	2,4-Di CH ₃	33.46 \pm 1.21	307.04 \pm 2.74
3m	4-Ph	25.43 \pm 0.93	> 500
Trolox [®]		50.28 \pm 0.54	36.27 \pm 0.49

^aValues are expressed as mean \pm SEM for three independent experiments.

DPPH assay: DPPH radical scavenging activity of the synthesized compounds was determined by the method described by Lamaison *et al.*⁹, based on the reduction of methanolic solution of the colored DPPH radical. From the IC₅₀ values (Table-1), compound **3b** having 2,4-dimethoxy group showed significant DPPH scavenging activity (IC₅₀ = 66.73 μm) in comparison to Trolox, a hydrophilic analogue of vitamin E (IC₅₀ = 36.27 μm).

ACKNOWLEDGEMENT

This work was supported by a grant from the Research Council of Tehran University of Medical Sciences.

REFERENCES

1. R.K. Fidelus, *Cell. Immunol.*, **113**, 175 (1988).
2. R.G. Cutter, *Age*, **18**, 91 (1995).
3. G. Poli and M. Parola, *Free Radical Biol. Med.*, **22**, 287 (1997).
4. D.A. Cox and M.L. Cohen, *Pharmacol. Rev.*, **48**, 3 (1996).
5. T. Finkel and N.J.H. Brook, *Nature*, **408**, 239 (2000).
6. W. Kemnitzer, J. Drewe, S. Jiang, H. Zhang, Y. Wang, J. Zhao, S. Jia, J. Herich, D. Labreque, R. Storer, K. Meerovitch, D. Bouffard, R. Rej, R. Denis, C. Blasic, S. Lamothe, G. Attardo, H. Gourdeau, B. Tseng, S. Kasibhatta and S. X. Cai, *J. Med. Chem.*, **47**, 6299 (2004).
7. W. Kemnitzer, S. Kasibhatta, S. Jiang, H. Zhang, J. Zhao, S. Jia, L. Xu, C. Crogan-Grundy, R. Denis, N. Barriault, L. Vaillancourt, S. Charron, J. Dodd, G. Attardo, D. Labrecque, S. Lamothe, H. Gourdeau, B. Tseng, J. Drewe and S.X. Cai, *Bioorg. Med. Chem. Lett.*, **15**, 4745 (2005).
8. I.F. Benzie and J.J. Strain, *Anal. Biochem.*, **239**, 70 (1996).
9. J.I. Lamaison, C.P.-Freytet and C.A. Carnet, *Pharm. Acta Helv.*, **66**, 185 (1991).

(Received: 4 January 2006; Accepted: 18 September 2006)

AJC-5105